All Stories

  1. Nanobody-drug conjugates for targeting specific GPCR pairs

    Article • PLoS Biology, November 2025, PLOS

    Dr Bryan L Roth

  2. The polypharmacology of psychedelics reveals multiple targets for potential therapeutics

    Article • Neuron, October 2025, Elsevier

    Dr Bryan L Roth

  3. Psychedelics as Transformative Therapeutics

    Article • American Journal of Psychiatry, May 2023, American Psychiatric Association

    Dr Bryan L Roth

  4. Harnessing Ion-Binding Sites for GPCR Pharmacology

    Article • Pharmacological Reviews, September 2019, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Bryan L Roth

  5. Biased signaling of the proton-sensing receptor OGR1 by benzodiazepines

    Article • The FASEB Journal, February 2018, Federation of American Societies For Experimental Biology (FASEB)

    Dr Deepak Deshpande, rey panettieri, Dr Bryan L Roth

  6. Protamine is an antagonist of apelin receptor, and its activity is reversed by heparin

    Article • The FASEB Journal, February 2017, Federation of American Societies For Experimental Biology (FASEB)

    Dr Bryan L Roth

  7. Psilocybin for depression and anxiety associated with life-threatening illnesses

    Article • Journal of Psychopharmacology, November 2016, SAGE Publications

    Dr Bryan L Roth

  8. Discovery and Characterization of Novel GPR39 Agonists Allosterically Modulated by Zinc

    Article • Molecular Pharmacology, October 2016, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Bryan L Roth

  9. DREADDs (Designer Receptors Exclusively Activated by Designer Drugs): Chemogenetic Tools with Therapeutic Utility

    Article • The Annual Review of Pharmacology and Toxicology, January 2015, Annual Reviews

    Dr Bryan L Roth